Impact of MET inhibitors on survival among patients (pts) with <i>MET</i> exon 14 mutant (<i>MET</i>del14) non-small cell lung cancer (NSCLC).
Mark M. Awad(Memorial Sloan Kettering Cancer Center), Rebecca S. Heist(Massachusetts General Hospital), Suzanne E. Dahlberg(Dana-Farber Cancer Institute), Shirish M. Gadgeel(Chinese University of Hong Kong), Daniel B. Costa(Beth Israel Deaconess Medical Center), Pasi A. Jänne(Harvard University), Sinéad Noonan(University of Colorado Anschutz Medical Campus), Patrick M. Forde(Sidney Kimmel Comprehensive Cancer Center), Alexander Drilon(Memorial Sloan Kettering Cancer Center), Tony Mok(Chinese University of Hong Kong), Yoko Fukuda(Memorial Hospital), D. Ross Camidge(University of Colorado Denver), Viola W. Zhu(University of California, Irvine), Conor Steuer(Emory University), Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center), Jeffrey W. Clark(Massachusetts General Hospital), Giulia C. Leonardi(Harvard University), Lynette M. Sholl(Brigham and Women's Hospital), Sasha Kravets(Dana-Farber Cancer Institute)
Cited by 32
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k